Literature DB >> 20689764

Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

Liliane Meunier1, Marie-Line Puiffe, Cécile Le Page, Abdelali Filali-Mouhim, Mario Chevrette, Patricia N Tonin, Diane M Provencher, Anne-Marie Mes-Masson.   

Abstract

A third of patients with epithelial ovarian cancer (EOC) present ascites. The cellular fraction of ascites often consists of EOC cells, lymphocytes, and mesothelial cells, whereas the acellular fraction contains cytokines and angiogenic factors. Clinically, the presence of ascites correlates with intraperitoneal and retroperitoneal tumor spread. We have used OV-90, a tumorigenic EOC cell line derived from the malignant ascites of a chemonaive ovarian cancer patient, as a model to assess the effect of ascites on migration potential using an in vitro wound-healing assay. A recent report of an invasion assay described the effect of ascites on the invasion potential of the OV-90 cell line. Ascites sampled from 31 ovarian cancer patients were tested and compared with either 5% fetal bovine serum or no serum for their nonstimulatory or stimulatory effect on the migration potential of the OV-90 cell line. A supervised analysis of data generated by the Affymetrix HG-U133A GeneChip identified differentially expressed genes from OV-90 cells exposed to ascites that had either a nonstimulatory or a stimulatory effect on migration. Ten genes (IRS2, CTSD, NRAS, MLXIP, HMGCR, LAMP1, ETS2, NID1, SMARCD1, and CD44) were upregulated in OV-90 cells exposed to ascites, allowing a nonstimulatory effect on cell migration. These findings were validated by quantitative polymerase chain reaction. In addition, the gene expression of IRS2 and MLXIP each correlated with prognosis when their expression was assessed in an independent set of primary cultures established from ovarian ascites. This study revealed novel candidates that may play a role in ovarian cancer cell migration.

Entities:  

Year:  2010        PMID: 20689764      PMCID: PMC2915414          DOI: 10.1593/tlo.10103

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  34 in total

Review 1.  Open source software for the analysis of microarray data.

Authors:  Sandrine Dudoit; Robert C Gentleman; John Quackenbush
Journal:  Biotechniques       Date:  2003-03       Impact factor: 1.993

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

Authors:  T Strobel; L Swanson; S A Cannistra
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

5.  Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.

Authors:  N Jandu; M Richardson; G Singh; H Hirte; M W C Hatton
Journal:  Int J Gynecol Cancer       Date:  2006 Jul-Aug       Impact factor: 3.437

6.  Involvement of insulin receptor substrate 2 in mammary tumor metastasis.

Authors:  Julie A Nagle; Zhefu Ma; Maura A Byrne; Morris F White; Leslie M Shaw
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 7.  Early events in ovarian oncogenesis.

Authors:  Dusica Cvetkovic
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

8.  CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance.

Authors:  Pamela Klingbeil; Rachid Marhaba; Thorsten Jung; Robert Kirmse; Thomas Ludwig; Margot Zöller
Journal:  Mol Cancer Res       Date:  2009-02-10       Impact factor: 5.852

9.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

10.  Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.

Authors:  N Ahmed; C Riley; K Oliva; G Rice; M Quinn
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more
  18 in total

1.  Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Authors:  Tamal Das; Liliane Meunier; Laurent Barbe; Diane Provencher; Olivier Guenat; Thomas Gervais; Anne-Marie Mes-Masson
Journal:  Biomicrofluidics       Date:  2013-01-10       Impact factor: 2.800

Review 2.  Histone H2A isoforms: Potential implications in epigenome plasticity and diseases in eukaryotes.

Authors:  Sanket Shah; Tripti Verma; Mudasir Rashid; Nikhil Gadewal; Sanjay Gupta
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

3.  Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.

Authors:  Mark A Marzinke; Caitlin H Choi; Li Chen; Ie-Ming Shih; Daniel W Chan; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2012-11-19       Impact factor: 5.911

4.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Authors:  Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

Review 5.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

6.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Authors:  Hubert Fleury; Laudine Communal; Euridice Carmona; Lise Portelance; Suzanna L Arcand; Kurosh Rahimi; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Genes Cancer       Date:  2015-09

7.  Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells.

Authors:  Marie Cohen; Sandra Pierredon; Christine Wuillemin; Florence Delie; Patrick Petignat
Journal:  Oncoscience       Date:  2014-04-30

8.  Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.

Authors:  Nadzeya Goncharenko-Khaider; Isabelle Matte; Denis Lane; Claudine Rancourt; Alain Piché
Journal:  Mol Cancer       Date:  2012-11-17       Impact factor: 27.401

9.  Characterization of ascites-derived ovarian tumor cells from spontaneously occurring ovarian tumors of the chicken: evidence for E-cadherin upregulation.

Authors:  Anupama Tiwari; Jill A Hadley; Gilbert L Hendricks; Robert G Elkin; Timothy Cooper; Ramesh Ramachandran
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3.

Authors:  Zhengyi Ruan; Jianhua Liu; Yanping Kuang
Journal:  Exp Ther Med       Date:  2015-10-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.